Charles Schwab Investment Management Inc. Purchases 26,870 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

Charles Schwab Investment Management Inc. increased its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 9.3% during the third quarter, Holdings Channel reports. The fund owned 316,134 shares of the company’s stock after purchasing an additional 26,870 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Stoke Therapeutics were worth $3,885,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Intech Investment Management LLC bought a new stake in shares of Stoke Therapeutics during the third quarter worth $160,000. Los Angeles Capital Management LLC lifted its position in Stoke Therapeutics by 54.3% during the 3rd quarter. Los Angeles Capital Management LLC now owns 103,005 shares of the company’s stock worth $1,266,000 after buying an additional 36,240 shares in the last quarter. Mesirow Financial Investment Management Inc. acquired a new position in Stoke Therapeutics during the 3rd quarter worth about $192,000. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in Stoke Therapeutics by 426.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock worth $18,741,000 after acquiring an additional 1,123,500 shares during the last quarter. Finally, Lynx1 Capital Management LP increased its position in Stoke Therapeutics by 40.3% in the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock valued at $70,052,000 after acquiring an additional 1,488,371 shares in the last quarter.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $12.07, for a total value of $120,700.00. Following the sale, the insider now directly owns 51,277 shares in the company, valued at approximately $618,913.39. This trade represents a 16.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Skorpios Trust sold 1,937,500 shares of Stoke Therapeutics stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the transaction, the insider now directly owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. This represents a 17.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,000,349 shares of company stock worth $28,031,296 in the last ninety days. Company insiders own 11.30% of the company’s stock.

Stoke Therapeutics Stock Down 2.1 %

NASDAQ:STOK opened at $12.06 on Friday. Stoke Therapeutics, Inc. has a 12-month low of $4.09 and a 12-month high of $17.58. The stock’s fifty day simple moving average is $12.49 and its 200-day simple moving average is $13.64. The firm has a market capitalization of $638.82 million, a P/E ratio of -5.74 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.05. The firm had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, equities research analysts expect that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on STOK. Leerink Partners started coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Stoke Therapeutics presently has an average rating of “Buy” and a consensus price target of $20.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.